The ban on 340B pricing on orphan drugs for over 1,000 hospitals may give companies that make drugs used primarily for common diseases or conditions a strong financial incentive to get an orphan designation for those drugs, a federal watchdog agency recently reminded Congress.
The U.S. Health and Human Services (HHS) Office of Inspector General included that finding, first made in an October report on Medicare spending on orphan drugs, in its latest semiannual report to Congress. OIG delivered the biannual report to lawmakers on Dec. 2.
The ban on 340B pricing on orphan drugs for over 1,000 hospitals may give companies that make drugs used primarily for common diseases or conditions a strong financial incentive to get an orphan designation for those drugs, a federal watchdog agency recently reminded Congress.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
